DE60225141D1 - Verfahren zur erhöhung der in vivo wirksamkeit vonugetieren - Google Patents
Verfahren zur erhöhung der in vivo wirksamkeit vonugetierenInfo
- Publication number
- DE60225141D1 DE60225141D1 DE60225141T DE60225141T DE60225141D1 DE 60225141 D1 DE60225141 D1 DE 60225141D1 DE 60225141 T DE60225141 T DE 60225141T DE 60225141 T DE60225141 T DE 60225141T DE 60225141 D1 DE60225141 D1 DE 60225141D1
- Authority
- DE
- Germany
- Prior art keywords
- effectiveness
- vivo
- nucleic acid
- respiratory
- acid molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30307101P | 2001-07-06 | 2001-07-06 | |
US303071P | 2001-07-06 | ||
PCT/CA2002/001046 WO2003004511A2 (en) | 2001-07-06 | 2002-07-08 | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60225141D1 true DE60225141D1 (de) | 2008-04-03 |
DE60225141T2 DE60225141T2 (de) | 2009-03-05 |
Family
ID=23170407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60225141T Expired - Lifetime DE60225141T2 (de) | 2001-07-06 | 2002-07-08 | Verfahren zur erhöhung der in vivo wirksamkeit von oligonukleotiden und zur entzündungshemmung in säugetieren |
Country Status (13)
Country | Link |
---|---|
US (2) | US7745420B2 (de) |
EP (1) | EP1406667B1 (de) |
JP (1) | JP4903984B2 (de) |
AT (1) | ATE386548T1 (de) |
AU (1) | AU2002319033B2 (de) |
CA (1) | CA2451738C (de) |
DE (1) | DE60225141T2 (de) |
DK (1) | DK1406667T3 (de) |
ES (1) | ES2301659T3 (de) |
MX (1) | MXPA04000162A (de) |
NZ (1) | NZ530360A (de) |
PT (1) | PT1406667E (de) |
WO (1) | WO2003004511A2 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2584457C (en) * | 2004-10-29 | 2012-10-23 | Topigen Pharmaceuticals Inc. | Antisense oligonucleotides for treating allergy and neoplastic cell proliferation |
EP2049664B1 (de) | 2006-08-11 | 2011-09-14 | Prosensa Technologies B.V. | Einzelsträngige Oligonukleotide, welche komplementär zu repetitiven Elementen sind, zur Behandlung von DNS-Wiederholungen-Instabilitäts-assoziierten Erkrankungen |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
DK2203173T3 (en) | 2007-10-26 | 2016-02-29 | Academisch Ziekenhuis Leiden | Materials and methods for prevention of muscle diseases |
EP2119783A1 (de) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel |
EP2285961A4 (de) * | 2008-05-15 | 2012-10-17 | Topigen Pharmaceuticals Inc | Oligonukleotide zur behandlung von entzündungen und neoplastischer zellvermehrung |
WO2010048731A1 (en) * | 2008-10-31 | 2010-05-06 | Christopher John Ong | Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents |
EP2401023B1 (de) * | 2009-02-26 | 2016-04-20 | Advanced Cooling Therapy, Inc. | Vorrichtungen zur patiententemperaturkontrolle |
US9326890B2 (en) | 2009-02-26 | 2016-05-03 | Advanced Cooling Therapy, Inc. | Devices and methods for controlling patient temperature |
US9622909B2 (en) | 2009-02-26 | 2017-04-18 | Advanced Cooling Therapy, Inc. | Devices and methods for controlling patient temperature |
US9301871B2 (en) | 2009-02-26 | 2016-04-05 | Advanced Cooling Therapy, Inc. | Devices and methods for controlling patient temperature |
AU2012220299A1 (en) * | 2011-02-24 | 2013-09-12 | Pharmaxis Ltd | Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine |
CN104203289B (zh) | 2012-01-27 | 2020-11-03 | 比奥马林技术公司 | 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
US9272016B2 (en) * | 2012-04-20 | 2016-03-01 | University Of Iowa Research Foundation | Methods to enhance RNAi oligonucleotide delivery to respiratory epithelial cells |
RS56319B1 (sr) * | 2012-04-23 | 2017-12-29 | Biomarin Tech Bv | Oligonukleotidi koji moduliraju rnk sa poboljšanim karakteristikama za lečenje neuromišićnih poremećaja |
FR3057774A1 (fr) | 2016-10-21 | 2018-04-27 | Museum National D'histoire Naturelle | Derives de la purine pour leur utilisation dans le traitement ou la prevention de maladies dues a une mutation non-sens |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3337530A (en) * | 1965-09-20 | 1967-08-22 | Upjohn Co | Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety |
JPH01173818A (ja) * | 1987-12-28 | 1989-07-10 | Aisin Aw Co Ltd | 車両用ナビゲーション装置 |
US5523205A (en) * | 1988-08-02 | 1996-06-04 | Institut Pasteur | DNA probes specific for hemolytic listeria |
US5646265A (en) * | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5112961A (en) * | 1990-07-18 | 1992-05-12 | Schering Corporation | Dna encoding subunits of a high affinity gm-csf receptor |
CA2102224A1 (en) * | 1991-04-19 | 1992-10-20 | Toshio Kitamura | Human interleukin-3-receptor component |
US5872242A (en) | 1992-10-05 | 1999-02-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
GB9301000D0 (en) * | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
US6077668A (en) * | 1993-04-15 | 2000-06-20 | University Of Rochester | Highly sensitive multimeric nucleic acid probes |
CA2235420A1 (en) * | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
DE69934227T2 (de) * | 1998-06-19 | 2007-10-04 | Mcgill University, Montreal | Auf Beta-Arabinose und dessen Analoga basierte Antisense-Oligonukleotide |
EP1102786A4 (de) * | 1998-08-03 | 2002-03-06 | Univ East Carolina | Antisense-oligonukleotide mit geringem adenosingehalt, zubereitung, kit und behandlungsmethoden |
US6175004B1 (en) * | 1998-09-01 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine |
CN1330513A (zh) | 1999-04-06 | 2002-01-09 | 东卡罗来纳大学 | 低腺苷反义寡核苷酸、组合物、试剂盒及与支气管紧缩、肺炎、过敏及表面活性剂缺失相关的通气途径疾病的治疗方法 |
-
2002
- 2002-07-08 AU AU2002319033A patent/AU2002319033B2/en not_active Ceased
- 2002-07-08 PT PT02748499T patent/PT1406667E/pt unknown
- 2002-07-08 WO PCT/CA2002/001046 patent/WO2003004511A2/en active IP Right Grant
- 2002-07-08 AT AT02748499T patent/ATE386548T1/de active
- 2002-07-08 DE DE60225141T patent/DE60225141T2/de not_active Expired - Lifetime
- 2002-07-08 NZ NZ530360A patent/NZ530360A/en not_active IP Right Cessation
- 2002-07-08 CA CA2451738A patent/CA2451738C/en not_active Expired - Fee Related
- 2002-07-08 JP JP2003510677A patent/JP4903984B2/ja not_active Expired - Fee Related
- 2002-07-08 EP EP02748499A patent/EP1406667B1/de not_active Expired - Lifetime
- 2002-07-08 ES ES02748499T patent/ES2301659T3/es not_active Expired - Lifetime
- 2002-07-08 MX MXPA04000162A patent/MXPA04000162A/es active IP Right Grant
- 2002-07-08 DK DK02748499T patent/DK1406667T3/da active
- 2002-07-08 US US10/482,949 patent/US7745420B2/en not_active Expired - Fee Related
-
2009
- 2009-05-06 US US12/436,493 patent/US20100286235A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100286235A1 (en) | 2010-11-11 |
PT1406667E (pt) | 2008-05-23 |
NZ530360A (en) | 2006-01-27 |
CA2451738C (en) | 2013-09-17 |
EP1406667B1 (de) | 2008-02-20 |
CA2451738A1 (en) | 2003-01-16 |
WO2003004511A2 (en) | 2003-01-16 |
DK1406667T3 (da) | 2008-06-16 |
JP2004532900A (ja) | 2004-10-28 |
WO2003004511A3 (en) | 2003-07-10 |
US7745420B2 (en) | 2010-06-29 |
US20050032723A1 (en) | 2005-02-10 |
EP1406667A2 (de) | 2004-04-14 |
ATE386548T1 (de) | 2008-03-15 |
DE60225141T2 (de) | 2009-03-05 |
MXPA04000162A (es) | 2006-05-22 |
JP4903984B2 (ja) | 2012-03-28 |
AU2002319033B2 (en) | 2008-01-10 |
ES2301659T3 (es) | 2008-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60225141D1 (de) | Verfahren zur erhöhung der in vivo wirksamkeit vonugetieren | |
US20060229271A1 (en) | Methods for treating infectious disease exacerbated asthma | |
RU2487716C2 (ru) | Новые структуры малых интерферирующих рнк (sirna) | |
BR0107934A (pt) | Carboxamidas de pirimidina úteis como inibidores de isozimas pde4 | |
SG146649A1 (en) | Mucoactive agents for treating a pulmonary disease | |
SE0200356D0 (sv) | Novel use | |
JP2011500003A5 (de) | ||
EA017847B1 (ru) | Композиция для лечения респираторных синцитиальных вирусов | |
DK0981534T3 (da) | Dinukleotider og deres anvendelser | |
WO2005030787A3 (en) | Oligonucleotide compositions and methods for treating disease including inflammatory conditions | |
CN102099474B (zh) | 用于治疗炎症和赘生性细胞增殖的寡核苷酸 | |
JP2017512502A (ja) | 新規の二重らせんオリゴrnaおよびこれを含む線維症または呼吸器疾患の予防または治療用薬学組成物 | |
TW201919654A (zh) | 用於抑制α-ENaC表現之RNAi試劑及使用方法 | |
AU2002319033A1 (en) | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals | |
EP4015634A1 (de) | Sirna und zusammensetzungen zur prophylaktischen und therapeutischen behandlung von viruskrankheiten | |
BR0015270A (pt) | Método e composições para tratamento de doenças pulmonares | |
BRPI0413968A (pt) | composto de anel condensado e seu uso | |
KR20140014179A (ko) | 키메라 벡본 및 2-아미노-2''-데옥시아데노신을 포함하는 올리고뉴클레오티드 저해제 | |
RU2409666C2 (ru) | Модуляция rsv, piv и других респираторных вирусов с помощью rnai и ее применение | |
UY26423A1 (es) | Metodo y composiciones para el tratamiento de las enfermedades pulmonares |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8381 | Inventor (new situation) |
Inventor name: RENZI, PAOLO, WESTMOUNT, QUEBEC, CA Inventor name: ALLAM, MUSTAPHA, MONTREAL, QUEBEC, CA Inventor name: ALLAKHVERDI, ZOULFIA, MONTREAL, QUEBEC, CA |
|
8364 | No opposition during term of opposition |